Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability
Braz. j. med. biol. res
;
40(3): 383-389, Mar. 2007. tab
Artículo
en Inglés
| LILACS
| ID: lil-441763
ABSTRACT
The effect of proton pump inhibitors and Helicobacter pylori infection on the bioavailability of antibiotics is poorly understood. We determined the effects of 5-day oral administration of 60 mg lansoprazole on the bioavailability of clarithromycin in individuals with and without H. pylori infection. Thirteen H. pylori-infected and 10 non-infected healthy volunteers were enrolled in a study with an open-randomized two-period crossover design and a 21-day washout period between phases. Plasma concentrations of clarithromycin in subjects with and without lansoprazole pre-treatment were measured by liquid chromatography coupled to a tandem mass spectrometer. Clarithromycin Cmax and AUC0-10 h were significantly reduced after lansoprazole administration. In addition, lansoprazole treatment of the H. pylori-positive group resulted in a statistically significant greater reduction in Cmax (40 vs 15 percent) and AUC0-10 h (30 vs 10 percent) compared to lansoprazole-treated H. pylori-negative subjects. Thus, treatment with lansoprazole for 5 days reduced bioavailability of clarithromycin, irrespective of H. pylori status. This reduction, however, was even more pronounced in H. pylori-infected individuals.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Helicobacter pylori
/
Infecciones por Helicobacter
/
Claritromicina
/
Antiulcerosos
/
Antibacterianos
Tipo de estudio:
Ensayo Clínico Controlado
/
Estudio observacional
Límite:
Adulto
/
Humanos
Idioma:
Inglés
Revista:
Braz. j. med. biol. res
Asunto de la revista:
Biologia
/
Medicina
Año:
2007
Tipo del documento:
Artículo
País de afiliación:
Brasil
Institución/País de afiliación:
Universidade São Francisco/BR
Similares
MEDLINE
...
LILACS
LIS